Zacks Investment Research downgraded shares of Fresenius Medical Care Corporation (NYSE:FMS) from a hold rating to a sell rating in a report published on Tuesday.

According to Zacks, “Fresenius Medical Care has had a disappointing run on the bourse on a year-to-date basis. The company  ended the second quarter on a mixed note wherein adjusted earnings missed the Zacks Consensus Estimate, while revenues beat the same. Fresenius Medical Care reiterated its full-year guidance. We believe this is in tune with the company’s long-term objective or the ‘Growth Strategy 2020’, wherein it aims to drive revenues to $28 billion by 2020, corresponding to an average annual growth rate of 10%. A wide range of dialysis products, initiatives to attain market traction, solid international foothold, strategic acquisitions and divestments are major catalysts. Fresenius Medical Care has signed an agreement to acquire NxStage Medical for $2 billion. However, a tough regulatory environment, difficulties in boosting the profit margin in foreign legal paradigms and competition in the niche markets are major headwinds.”

Several other analysts have also recently issued reports on FMS. Nord/LB reaffirmed a buy rating on shares of Fresenius Medical Care Corporation in a report on Wednesday, June 28th. Royal Bank Of Canada reissued a hold rating and set a $44.00 price objective on shares of Fresenius Medical Care Corporation in a report on Wednesday, July 5th. UBS AG reissued a sell rating on shares of Fresenius Medical Care Corporation in a report on Tuesday, July 4th. BidaskClub downgraded shares of Fresenius Medical Care Corporation from a strong-buy rating to a buy rating in a research report on Monday, July 24th. Finally, DZ Bank AG reissued a buy rating on shares of Fresenius Medical Care Corporation in a research report on Monday, August 7th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. The company has an average rating of Hold and an average target price of $48.67.

Shares of Fresenius Medical Care Corporation (NYSE FMS) traded up 0.38% during mid-day trading on Tuesday, hitting $49.91. 131,141 shares of the stock traded hands. The stock has a 50-day moving average of $47.80 and a 200 day moving average of $46.49. Fresenius Medical Care Corporation has a one year low of $38.05 and a one year high of $50.22. The stock has a market cap of $30.63 billion, a PE ratio of 21.42 and a beta of 0.48.

Fresenius Medical Care Corporation (NYSE:FMS) last announced its earnings results on Tuesday, August 1st. The company reported $0.48 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.53 by ($0.05). The business had revenue of $4.47 billion during the quarter, compared to analyst estimates of $5.20 billion. Fresenius Medical Care Corporation had a net margin of 7.06% and a return on equity of 11.57%. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.96 earnings per share. Equities analysts predict that Fresenius Medical Care Corporation will post $2.34 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Marea Informative and is owned by of Marea Informative. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at http://www.mareainformativa.com/fresenius-medical-care-corporation-fms-lowered-to-sell-at-zacks-investment-research/115838/.

Several large investors have recently modified their holdings of the business. Level Four Advisory Services LLC lifted its position in shares of Fresenius Medical Care Corporation by 0.5% in the 1st quarter. Level Four Advisory Services LLC now owns 11,434 shares of the company’s stock worth $478,000 after buying an additional 58 shares during the last quarter. UBS Asset Management Americas Inc. boosted its holdings in shares of Fresenius Medical Care Corporation by 3.6% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock valued at $114,000 after buying an additional 81 shares during the period. Greenleaf Trust boosted its holdings in shares of Fresenius Medical Care Corporation by 2.6% in the 2nd quarter. Greenleaf Trust now owns 4,992 shares of the company’s stock valued at $241,000 after buying an additional 126 shares during the period. Sawtooth Solutions LLC boosted its holdings in shares of Fresenius Medical Care Corporation by 2.9% in the 2nd quarter. Sawtooth Solutions LLC now owns 4,887 shares of the company’s stock valued at $236,000 after buying an additional 137 shares during the period. Finally, Wrapmanager Inc. boosted its holdings in shares of Fresenius Medical Care Corporation by 2.4% in the 2nd quarter. Wrapmanager Inc. now owns 7,392 shares of the company’s stock valued at $357,000 after buying an additional 170 shares during the period. 2.61% of the stock is currently owned by institutional investors.

Fresenius Medical Care Corporation Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Analyst Recommendations for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Stock Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related stocks with our FREE daily email newsletter.